- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evidence Shows Improved OS With Delayed Radiation Following Glioblastoma Surgery
The UCSF study identified a window of 30 to 35 days post surgery, following surgery in patients with glioblastoma multiforme, when delayed radiation significantly improved OS and PFS.
Patients with newly diagnosed (GBM) have significantly better overall survival when there is a short delay between surgery and the start of radiation therapy, investigators say.
The optimal time to start radiation in patients with GBM is controversial, with some studies showing worse outcomes among patients for whom therapy is delayed and others suggesting that a short delay may not be harmful or may even be beneficial, said Seunggu Han, MD, a neurosurgery resident at the University of California San Francisco (UCSF), at the Congress of Neurological Surgeons (CNS) 2014 Annual Meeting here.
"With most other malignancies — , lung cancer — it's very clear that even if you delay radiation a little bit, outcomes are significantly worse, but it's beginning to look like it's not quite the same for glioblastoma," he said in an interview with Medscape Medical News.
Read the complete article on Medscape: http://bit.ly/1vUdeyJ
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
